Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Reply to Dorgham Et Al., “Considering Personalized Interferon Beta Therapy for Covid-19” Publisher Pubmed



Davoudimonfared E1 ; Khalili H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Source: Antimicrobial Agents and Chemotherapy Published:2021


Abstract

[No abstract available]
Related Docs
1. The Role of Type I Interferon in the Treatment of Covid-19, Journal of Medical Virology (2022)
2. Immunoediting in Sars-Cov-2: Mutual Relationship Between the Virus and the Host, International Immunopharmacology (2022)
3. The Role of Sars-Cov-2 Accessory Proteins in Immune Evasion, Biomedicine and Pharmacotherapy (2022)
4. Interferon-Beta Offers Promising Avenues to Covid-19 Treatment: A Systematic Review and Meta-Analysis of Clinical Trial Studies, Naunyn-Schmiedeberg's Archives of Pharmacology (2021)
5. Interferon Therapy in Patients With Sars, Mers, and Covid-19: A Systematic Review and Meta-Analysis of Clinical Studies, European Journal of Pharmacology (2021)
6. The Importance of Accessory Protein Variants in the Pathogenicity of Sars-Cov-2, Archives of Biochemistry and Biophysics (2022)
Experts (# of related papers)
Nima Rezaei (3)
Maryam Nourizadeh (1)